Tests LY4584180 in adults with previously treated blood cancers
Tests LY4584180 in adults with lymphoma that returned after earlier treatment.
Plain-language title generated from the registry record
Registry title: A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers
Key facts
- Where
- Atlanta, Boston, Columbus, Dallas, Denver, Duarte, Houston, Los Angeles, Miami, Milwaukee, Nashville, New York, Portland, Rochester, San Francisco, Sarasota, Scottsdale, and Seattle, United StatesSee the 21 sites
- Phase
- Phase 1
Where in United States
- Emory University HospitalAtlanta, United StatesTaking people
- Dana-Farber Cancer InstituteBoston, United StatesTaking people
- Massachusetts General HospitalBoston, United StatesTaking people
- The Ohio State University (OSU)Columbus, United StatesTaking people
- Texas Oncology - DFW (Sammons CC)Dallas, United StatesTaking people
- Colorado Blood Cancer InstituteDenver, United StatesTaking people
- City of HopeDuarte, United StatesTaking people
- Baylor College of MedicineHouston, United StatesNot yet recruiting
- University of California, Los Angeles (UCLA) - Medical CenterLos Angeles, United StatesTaking people
- University of Miami - Sylvester Cancer CenterMiami, United StatesTaking people
- Froedtert Hospital and the Medical College of WisconsinMilwaukee, United StatesTaking people
- Sarah Cannon Research InstituteNashville, United StatesTaking people
- Vanderbilt University Medical CenterNashville, United StatesTaking people
- Columbia UniversityNew York, United StatesTaking people
- Oregon Health & Science University (OHSU)Portland, United StatesNot yet recruiting
- Mayo Clinic - RochesterRochester, United StatesTaking people
- University of RochesterRochester, United StatesTaking people
- University of California San Francisco (UCSF) - Helen Diller Family Comprehensive Cancer CenterSan Francisco, United StatesTaking people
- Florida Cancer Specialists - SarasotaSarasota, United StatesTaking people
- Mayo Clinic ScottsdaleScottsdale, United StatesTaking people
- University of Washington - Fred Hutchinson Cancer Center (Seattle Cancer Care Alliance)Seattle, United StatesTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Trial details
- Who runs it
- Eli Lilly and Company
- Trial code
- NCT07226843EU 2025-523601-16-00
- Record updated
- 4 November 2026
- Original description
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.Read full original descriptionShow less
NOVA-BCL6-1, A First-in-Human, Multicenter Phase 1a/1b Study to Investigate Safety, Tolerability, Pharmacokinetics, and Efficacy of LY4584180 in Adult Participants With Previously Treated Hematologic Malignancies
The main purpose of this study is to evaluate safety and efficacy, and measure how much LY4584180 gets into the bloodstream and how long it takes the body to eliminate it in patients with previously treated blood cancers. For each participant, the study could last about 9 months or possibly longer including screening.
Inclusion: Has been treated for the following blood cancers and has received at least 2 prior lines of systemic therapy or not eligible for available therapy:; Diffuse large B-cell lymphoma - not otherwise specified; High-grade B-cell lymphoma; Diffuse large B-cell lymphoma - transformed from indolent lymphomas; Follicular large B-cell lymphoma; Follicular lymphoma; Other non-Hodgkin lymphoma; Has measurable disease; Has discontinued all previous treatments for cancer and has recovered from the immediate effects of therapy.
Exclusion: Has known central nervous system (CNS) involvement by systemic lymphoma. Patients with previous treatment for CNS involvement who are neurologically stable and without evidence of active CNS disease may be eligible and enrolled if a compelling clinical rationale is provided by the Investigator and with documented Sponsor approval; Has an active second cancer; Has known Cytomegalovirus infection. Participants with negative status are eligible; Has known hepatitis B or C infection or uncontrolled HIV; Has known significant heart disease.